Risdiplam

證據等級: L5

預測適應症: 1 個

Risdiplam: From Spinal Muscular Atrophy to Acne (Disease)

One-Sentence Summary

Risdiplam is an SMN2 pre-mRNA splicing modifier developed for spinal muscular atrophy (SMA); no marketing authorization or approved-indication text is currently on file for this product. The TxGNN model predicts a possible effect in Acne (disease), with a very high raw score (99.45%) but zero supporting clinical trials and zero publications. The model's own mechanistic rationale flags this pairing as lacking any known biological link, so the prediction should be treated as a candidate signal only, not evidence.

Quick Overview

Item	Content
Original Indication	Spinal Muscular Atrophy (SMA) — per repurposing rationale text; formal MOA/indication fields are a data gap
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.45%
Evidence Level	L5
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is currently unavailable (original_moa: Data Gap). Based on the information available in this evidence pack, Risdiplam is known as an SMN2 splicing modifier that promotes inclusion of exon 7 in SMN2 pre-mRNA, restoring functional SMN protein in motor neurons — the basis for its use in spinal muscular atrophy.

There is no known or biologically plausible mechanistic pathway connecting SMN2 splicing modulation to acne pathophysiology (sebaceous gland activity, androgen signaling, follicular hyperkeratinization, or C. acnes-driven inflammation). The evidence pack's own rationale explicitly characterizes this prediction as lacking mechanistic support and flags it as a possible spurious association arising from the knowledge graph rather than a genuine biological signal.

Given the absence of both original-indication/MOA data and any mechanistic bridge to acne, this prediction should be treated purely as a TxGNN model output pending independent biological validation — it does not currently meet the bar for hypothesis-driven follow-up.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a raw TxGNN score (L5, S0) with no clinical trials, no literature, and no plausible mechanistic link identified in the evidence itself; the drug is also unmarketed with no available regulatory or safety data, and the original indication/MOA data gap (DG001, DG002) blocks even a preliminary safety assessment.

To proceed, the following is needed:

TFDA/regulatory package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed original indication and mechanism of action data (DG002)
An independent mechanistic hypothesis linking SMN2 splicing to acne pathology before further evidence search is warranted
Ongoing monitoring for any future clinical trial or literature signal in dermatologic indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.